Key Highlights
- Shares closed at $3.19 at last closing, down 2.15%, in penny-stock territory.
- Second-quarter 2026 Revenue was only about $2.3 million, down roughly 68% year over year, with a net loss of around $8.7 million that included a non-cash valuation allowance against deferred tax assets.
- Several unit sales were deferred to the following quarter on financing timing, and the company lost sales to a historically large customer.
- Sensus Healthcare held cash of about $15 million with no Debt and pointed to new reimbursement codes as potential tailwinds.
Penny stock Sensus Healthcare (NASDAQ:SRTS) is a medical-device company that makes superficial radiation therapy systems used to treat non-melanoma skin cancers and keloids, selling and placing its devices with physicians and clinics. Shares closed at $3.19 at last closing, down 2.15%.
Its results depend on device unit sales and their timing, its revenue and margins, customer concentration, and reimbursement trends, so it is exposed to Demand for its systems and to the lumpiness of device sales.
Latest Developments
In its second-quarter 2026 results, Sensus Healthcare reported revenue of only about $2.3 million, down roughly 68% year over year, with a net loss of around $8.7 million that included a non-cash valuation allowance against deferred tax assets, as it sold far fewer units, deferred several unit sales to the following quarter on financing timing, lost sales to a historically large customer, and shipped more lower-priced international units; it held cash of about $15 million with no debt and pointed to new reimbursement codes as potential tailwinds. Investors should verify the latest unit sales, customer concentration, and reimbursement developments directly from SEC filings, recognizing that part of the decline reflects timing and a non-cash charge.
Financial and Business Position
As a small-cap medical-device company, Sensus Healthcare's financial position is defined by its sharply lower revenue, its widened loss including a non-cash tax charge, and its clean Balance Sheet with cash and no debt. Investors should focus on revenue and unit sales, customer concentration, and reimbursement developments.
Stock-Market Context
SRTS shares closed at $3.19 at last closing, down 2.15%, keeping the stock in penny territory. The stock is a small-cap medical-device company whose shares are volatile and sensitive to unit-sales timing, customer concentration, and reimbursement, and the clean balance sheet and reimbursement tailwinds support the opportunity side of the story.
What Investors Should Watch
Watch revenue and unit sales, the net and operating loss, cash, customer concentration, and reimbursement developments such as new codes and proposed increases. Recognition of deferred unit sales combined with reimbursement tailwinds and customer Diversification would favor the opportunity interpretation.






Please wait processing your request...